ISPOR - Real World Treatment Patterns In Chronic Lymphocytic Leukemia Patients In The United States - Rituximab, The Most Commonly Used Agent

Full Text

Real World Treatment Patterns In Chronic Lymphocytic Leukemia Patients In The United States - Rituximab, The Most Commonly Used Agent

Abstract

Authors

J Brown S Shreay K Rai

Back to Volume 17, Issue 3

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now